X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LP0133 (delgocitinib) cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. It is under phase 3 clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: DKSH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 29, 2022
Details:
Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Japan Tobacco Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases. delgocitinib cream demonstrated a statistically significant dose-response relationship in the trial.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LEO 124249
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Japan Tobacco Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LEO 124249
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Japan Tobacco Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Japan Tobacco Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
